Stent developer Lombard Medical revives IPO plans and decreases deal size

By
A A A

Lombard Medical, which offers innovative stent-grafts for highly angled endovascular aortic repair, revived plans for its upcoming IPO and lowered the proposed deal size on Wednesday. The Oxfordshire, United Kingdom-based company postponed its IPO in early April but now plans to raise $55 million by offering 5.0 million shares at $11. The company had previously filed to offer 3.6 million shares at a range of $15 to $18. At the midpoint of the revised range, Lombard will raise 8% less in proceeds than previously anticipated.

Lombard Medical, which was founded in 2003 and booked $7 million in sales for the fiscal year ended December 31, 2013, plans to list on the NASDAQ under the symbol EVAR. It initially filed confidentially on January 22, 2014. Jefferies and Barclays are the joint bookrunners on the deal. It is expected to price on April 24, 2014 .




The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of The NASDAQ OMX Group, Inc.



This article appears in: News Headlines , IPOs

Referenced Stocks: EVAR

Renaissance Capital

Renaissance Capital

More from Renaissance Capital:

Related Videos

Stocks

Referenced

Most Active by Volume

89,070,840
  • $17.26 ▲ 3.23%
78,931,485
  • $7.02 ▲ 4.46%
77,555,734
  • $6.70 ▲ 6.69%
77,025,346
  • $24.66 ▲ 0.69%
74,713,335
  • $101.80 ▲ 1.82%
72,324,726
  • $7.64 ▲ 0.79%
57,112,188
  • $17.84 ▲ 55.27%
53,321,397
  • $18.01 ▼ 4.46%
As of 12/17/2014, 04:15 PM


Find a Credit Card

Select a credit card product by:
Select an offer:
Search
Data Provided by BankRate.com